Screener
BioCryst Pharmaceuticals BCRX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Finance lease liabilities | 1,092 | 1,312 |
| Royalty financing obligations | 43,808 | 38,455 |
| Deferred revenue | 12,320 | — |
| Total current liabilities | 208,846 | 196,066 |
| Operating lease liabilities | 10,603 | 8,571 |
| Finance lease liabilities | 849 | 1,441 |
| Royalty financing obligations | 382,981 | 427,233 |
| Secured term loan | 395,400 | — |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's total current liabilities?
- BioCryst Pharmaceuticals (BCRX) reported total current liabilities of $208.85M in Q2 2026.
- How has BioCryst Pharmaceuticals's total current liabilities changed year-over-year?
- BioCryst Pharmaceuticals's total current liabilities increased by 17.9% year-over-year, from $177.16M to $208.85M.
- What is the long-term trend for BioCryst Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's total current liabilities has grown at a 13.2% compound annual growth rate (CAGR), from $105.65M to $196.07M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about BioCryst Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude